MARKET COMPOSITE
LCI - Lannett Co., Inc.
Price
$0.00
+ 0.00 (0.00%)
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.
Financials
Quarterly financials
(USD)Mar 2023Q/Q
Revenue80.5MM-0%
Gross Profit15.2MM+6%
Cost Of Revenue64.3MM-1%
Operating Income-86.7MM-
Operating Expenses101.9MM-
Net Income-101.5MM-
R&D7.1MM+44%
G&A20.4MM+12%
Amortization1MM-29%
Interest Expense15.2MM-0%
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    Lannett Company, Inc. (OTCMKTS: LCIN) (the "Company" or "Lannett") today announced that, together with certain of its subsidiaries (collectively with the Company, as applicable, the "Company Parties"), it has entered into a Restructuring Support Agreement (the "RSA") with holders of more than 80% of its 7.750% senior secured notes due 2026 (the "Senior Secured Note Holders") and 100% of the lenders party to the Company's second lien credit and guaranty agreement (the "Second Lien Term Lenders",

    Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain a

    LANNETT SHARES UPDATE04-04-2023 10:55:00 AM

    Lannett Company, Inc. (NYSE: LCI) (the "Company") today shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.

    With major economic weakness possibly lurking around the corner, investors should consider targeting stocks to sell. Specifically, market participants should note securities that feature rising short borrow fees. As the name suggests, brokerage firms charge fees to clients who borrow shares for shorting purposes. Further, the more difficult the underlying security is to borrow, the higher the fee. On paper, rising borrowing costs indicate greater demand among short sellers, which is naturally be

    If you want to know who really controls Lannett Company, Inc. ( NYSE:LCI ), then you'll have to look at the makeup of...

    Lannett Company, Inc. (NYSE:LCI) Q2 2023 Earnings Call Transcript February 1, 2023 Operator: Greetings and welcome to the Lannett Company Fiscal 2023 Second Quarter Financial Results Conference Call. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Robert Jaffe, Investor Relations for Lannett Company. […]

    Lannett (LCI) delivered earnings and revenue surprises of 17.07% and 10.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

    Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2023 second quarter ended December 31, 2022.

    Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m. Eastern Time on February 6, 2023. Beginning February 7, 2023, the company's common stock will trade on a split-adjusted basis. The common stock will continue to trade on the New York Stock Exchange (NYSE) under the symbol "LCI," but will trade under the new CUSIP number 516012 200. The reverse stock split wa

    Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance.